By otakuyassine3@gmail.com 
Blue Trust Inc. increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 35.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,914 shares of the medical research company’s stock after purchasing an additional 2,865 shares during the period. Blue Trust Inc.’s holdings in Edwards Lifesciences were worth $808,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the company. Bowman & Co S.C. grew its holdings in shares of Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after buying an additional 148 shares during the last quarter. JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Seascape Capital Management raised its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares during the last quarter. Cooper Financial Group lifted its holdings in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after purchasing an additional 175 shares in the last quarter. Finally, Martin Capital Advisors LLP lifted its holdings in shares of Edwards Lifesciences by 0.7% during the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after purchasing an additional 186 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.
Insiders Place Their Bets
In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock worth $2,195,180 in the last quarter. 1.27% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
A number of analysts have recently commented on EW shares. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a research report on Thursday, January 16th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Piper Sandler decreased their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $78.48.
Edwards Lifesciences Trading Down 1.9 %
EW stock opened at $71.21 on Thursday. The company has a market cap of $42.00 billion, a price-to-earnings ratio of 10.28, a PEG ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $72.37 and a 200-day simple moving average of $70.06.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences and related companies with MarketBeat.com’s FREE daily email newsletter.